Filing Flows › TG Therapeutics (TGTX) › Q3 2026 › vs Q3 2025
TG Therapeutics (TGTX) Q3 2026 vs Q3 2025 (year over year)
TG Therapeutics's revenue rose $98.2M (+61%) from $162M in Q3 2025 to $260M in Q3 2026. The biggest changes: Product revenue, net +$80.7M (+51%); License, milestone, royalty and other revenue +$17.5M (+732%). Operating margin 33.0% against 18.2% (+14.9 pts).
TG Therapeutics, Q3 2026: revenue $260M (+61% year over year), operating margin 33.0%, net earnings $55.5M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 33.0% | 18.2% | +14.9 pts |
| Net margin | 21.3% | 241.7% | -220.4 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product revenue, net | $240M | $159M | $80.7M | +51% |
| License, milestone, royalty and other revenue | $19.9M | $2.4M | $17.5M | +732% |
| Revenue | $260M | $162M | $98.2M | +61% |
| Operating profit | $85.9M | $29.4M | $56.5M | +193% |
| Costs & expenses | $174M | $132M | $41.7M | +32% |
| Pre-tax earnings | $73.9M | $25.9M | $48.0M | +185% |
| Other expense, net | $12.0M | $3.5M | $8.6M | +248% |
| Cost of revenue | $42.1M | $28.1M | $14.0M | +50% |
| Net earnings | $55.5M | $391M | −$335M | -86% |
| Income tax | $18.4M | −$365M | $383M | — |
Questions
How much did TG Therapeutics's revenue grow year over year in Q3 2026?
TG Therapeutics's revenue rose $98.2M (+61%) from $162M in Q3 2025 to $260M in Q3 2026.
What drove TG Therapeutics's revenue change in Q3 2026?
Product revenue, net +$80.7M (+51%); License, milestone, royalty and other revenue +$17.5M (+732%).